Doxorubicin-Induced Cardiometabolic Disturbances: What Can We Do?

Isfahan University of Medical Sciences

Science Communicator Platform

Share By

Doxorubicin-Induced Cardiometabolic Disturbances: What Can We Do? Publisher

Avagimyan A^{1, 2} ; Pogosova N^{3, 4} ; Rizzo M⁵ ; Sarrafzadegan N²

Source: Frontiers in Clinical Diabetes and Healthcare Published:2025

Abstract

[No abstract available]

Style	Citing Format
MLA	Avagimyan A, et al.. "Doxorubicin-Induced Cardiometabolic Disturbances: What Can We Do?." Frontiers in Clinical Diabetes and Healthcare, vol. 6, no. , 2025, pp. -.
APA	Avagimyan A, Pogosova N, Rizzo M, Sarrafzadegan N (2025). Doxorubicin-Induced Cardiometabolic Disturbances: What Can We Do?. Frontiers in Clinical Diabetes and Healthcare, 6(), -.
Chicago	Avagimyan A, Pogosova N, Rizzo M, Sarrafzadegan N. "Doxorubicin-Induced Cardiometabolic Disturbances: What Can We Do?." Frontiers in Clinical Diabetes and Healthcare 6, no. (2025): -.
Harvard	Avagimyan A et al. (2025) 'Doxorubicin-Induced Cardiometabolic Disturbances: What Can We Do?', Frontiers in Clinical Diabetes and Healthcare, 6(), pp. -.
Vancouver	Avagimyan A, Pogosova N, Rizzo M, Sarrafzadegan N. Doxorubicin-Induced Cardiometabolic Disturbances: What Can We Do?. Frontiers in Clinical Diabetes and Healthcare. 2025;6():-.
BibTex	@article{ author = {Avagimyan A and Pogosova N and Rizzo M and Sarrafzadegan N}, title = {Doxorubicin-Induced Cardiometabolic Disturbances: What Can We Do?}, journal = {Frontiers in Clinical Diabetes and Healthcare}, volume = {6}, number = {}, pages = {-}, year = {2025} }
RIS	TY - JOUR AU - Avagimyan A AU - Pogosova N AU - Rizzo M AU - Sarrafzadegan N TI - Doxorubicin-Induced Cardiometabolic Disturbances: What Can We Do? JO - Frontiers in Clinical Diabetes and Healthcare VL - 6 IS - SP - EP - PY - 2025 ER -